Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153079 | 0.88 | KDM4E (0.43) | PARP1PARP15PARP3TYMSKDM4E | |
| SCHEMBL17895756 | 0.76 | PDK1 (0.35) | PARP1PARP15PARP3TYMSKDM4E | |
| SCHEMBL19153081 | 0.74 | PARP1 (0.38) | PARP1PARP15PARP3TYMSKDM4E | |
| SCHEMBL21663149 | 0.74 | ADORA3 (0.35) | L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL12199286 | 0.74 | KDM4E (0.36) | KDM4E | |
| SCHEMBL22383681 | 0.74 | PARP1 (0.35) | PARP1PARP15PARP3TYMSALDH1A1 | |
| SCHEMBL18711836 | 0.70 | PARP1 (0.62) | PARP1PARP15PARP3TYMSKDM4E | |
| SCHEMBL19152668 | 0.67 | PARP1 (0.39) | PARP1PARP15PARP3TYMSKDM4E | |
| SCHEMBL12488755 | 0.67 | CRBN (0.39) | PARP1PARP15PARP3TYMSKDM4E | |
| SCHEMBL15116441 | 0.66 | TYMS (0.63) | PARP1TYMSKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505519-B1 | PYRIDINAMINE-SUBSTITUTED HETEROTRICYCLO COMPOUNDS, PREPARATION THEREOF, AND USE IN MEDICINES | SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. | 2021-11-09 | — | — | US | disclosed |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
| EP-3505519-A1 | PYRIDINAMINE-SUBSTITUTED HETEROTRICYCLO COMPOUNDS, PREPARATION THEREOF, AND USE IN MEDICINES | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168088-B2 | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof | CYP2D6, PNPO, CYP2B6 | PARP1 1232/4885PARP15 1341/4885PARP3 733/4885 |
| US-20200039983-A1 | PYRIDYLAMINO SUBSTITUTED HETEROTRICYCLIC COMPOUNDS, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | CYP2D6, PNPO, CYP2B6 | PARP1 1232/4885PARP15 1341/4885PARP3 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.